Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164018 | 0.94 | SMYD3 (0.43) | EPHX1HPGDTSHROPRM1NPSR1 | |
| SCHEMBL4707897 | 0.89 | MFN2 (0.41) | EPHX1HPGDTSHRNPSR1F2 | |
| SCHEMBL6122370 | 0.83 | NAMPT (0.46) | HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4407443 | 0.81 | HTT (0.58) | EPHX1HPGDTSHRHTTL3MBTL1 | |
| SCHEMBL9609026 | 0.81 | HTT (0.58) | EPHX1HPGDTSHRHTTL3MBTL1 | |
| SCHEMBL6121069 | 0.79 | EPHX2 (0.47) | EPHX1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24113114 | 0.78 | TSHR (0.44) | HPGDTSHROPRM1NPSR1F2 | |
| SCHEMBL4707323 | 0.78 | TSHR (0.41) | TSHROPRM1NPSR1F2MEN1 | |
| SCHEMBL6123113 | 0.77 | SMN1; SMN2 (0.50) | MEN1KMT2ASMN1; SMN2SMYD3 | |
| SCHEMBL19902473 | 0.77 | NPC1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1879863-A1 | AMIDE RESORCINOL COMPOUNDS | Pfizer, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | EPHX1 2287/4885HPGD 1069/4885TSHR 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.